For patients with chronic lymphocytic leukemia (CLL) treated previously with venetoclax and Bruton’s tyrosine kinase ...

Alessandra Ferrajoli, MD, discusses the importance of supportive care in the management of patients with chronic lymphocytic ...

The FDA has approved updated drug labeling for Sandoz in the treatment of B-cell chronic lymphocytic leukemia.

Chronic lymphocytic leukemia (CLL) is a slow-growing cancer ... the disease will progress and help your doctor choose which treatment options to use. The genetic testing to find such changes ...

GEO-CM04S1 Improved Immune Response vs mRNA VaccineATLANTA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology ...

Nurix Therapeutics (NRIX) announced that the European Medicines Agency, or EMA, has granted PRIME designation for NX-5948, a highly selective ...

Despite the emergence of more effective treatments, mainly the combination of immunotherapy with fludarabine-based regimens, CLL remains incurable. These more intensive therapies achieve the ...

Allogene Therapeutics has dropped plans to target one of its allogeneic CAR-Ts at leukemia in the face of competition from ...

alone or in combination with other treatments, are necessary to establish their proper role in CLL. New therapeutic targets in chronic lymphocytic leukemia. Novel monoclonal antibodies and agents ...

The venetoclax-based regimen was associated with an approximate $8000 decrease in costs compared with the continuous Bruton ...

Cyrus M. Khan, MD, discussed recent advancements in CLL treatment, particularly the shift to nonchemotherapy options and the ...